Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
Other Liabilities
Editas Medicine Inc
Other Liabilities Peer Comparison
Competitive Other Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Editas Medicine Inc
NASDAQ:EDIT
|
Other Liabilities
$79.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Other Liabilities
$32.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
17%
|
CAGR 10-Years
25%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Liabilities
$25.8B
|
CAGR 3-Years
59%
|
CAGR 5-Years
29%
|
CAGR 10-Years
52%
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Liabilities
$6.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
0%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Liabilities
$1.2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
62%
|
CAGR 10-Years
32%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Liabilities
$1.1B
|
CAGR 3-Years
22%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
18%
|
See Also
What is Editas Medicine Inc's Other Liabilities?
Other Liabilities
79.5m
USD
Based on the financial report for Mar 31, 2024, Editas Medicine Inc's Other Liabilities amounts to 79.5m USD.
What is Editas Medicine Inc's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
-8%
Over the last year, the Other Liabilities growth was -11%.